What are the recommended immediate and follow‑up evaluations and management after orchiectomy for a testicular tumor?

Post-Orchiectomy Evaluation and Management for Testicular Tumors

All patients must undergo serial serum tumor marker (STM) measurements (AFP, β-hCG, and LDH) at appropriate half-life intervals after orchiectomy until normalization or plateau, combined with mandatory CT imaging of chest, abdomen, and pelvis to guide risk stratification and treatment decisions. 1, 2

Immediate Post-Orchiectomy Evaluation

Serum Tumor Markers

• Measure AFP, β-hCG, and LDH immediately after orchiectomy and repeat at appropriate half-life intervals (β-hCG: 24-36 hours; AFP: 5-7 days) until normalization, progression, or plateau development 2
• These nadir values are critical for IGCCCG risk stratification and must be obtained before initiating any chemotherapy 1, 2
• For borderline elevations (within 3× upper limit of normal), confirm a rising trend before making treatment decisions, as false positives occur 2
• Monitor elevated markers to establish nadir levels only if these values will influence treatment selection 2

Imaging Requirements

• CT scan with IV contrast of abdomen and pelvis is mandatory for all patients 1
• Chest imaging is required in all cases 2:
  • For seminoma: chest X-ray is preferred over CT 2
  • For non-seminoma: CT chest is preferred, particularly for patients who may receive adjuvant therapy 2
  • CT chest is mandatory if markers are elevated/rising or if metastases are detected on abdominal/pelvic imaging 2
• MRI of CNS is indicated for poor-prognosis patients, especially with choriocarcinoma/high β-hCG, multiple lung metastases, or cerebral symptoms 1
• PET scanning is not recommended for routine staging 1, 2

Risk Stratification and Staging

Clinical Stage Assignment

• Assign TNM-s category based on histology, imaging findings, and post-orchiectomy STM levels 2
• For metastatic disease (Stage IIC or III), use IGCCCG risk stratification (good, intermediate, or poor-risk) based on nadir STM levels, staging imaging, tumor histology, and presence/absence of non-pulmonary visceral metastases 1, 2

Management Coordination

• Post-orchiectomy management must be performed by highly experienced clinicians at centers with expertise in testicular cancer 1
• Management decisions should be based on imaging obtained within 4 weeks and STM within 10 days 2

Stage-Specific Management Pathways

Stage I Seminoma

• Surveillance is the recommended primary approach after orchiectomy (>80% cured with surgery alone) 2
• Adjuvant carboplatin or radiotherapy are less preferred alternatives that reduce relapse risk but do not improve cancer-specific survival 2

Stage I Non-Seminoma

• Risk stratification based on vascular invasion, tumor size, rete testis invasion, and embryonal carcinoma content 1
• Options include surveillance, chemotherapy, or retroperitoneal lymph node dissection (RPLND) based on risk factors 2

Stage IIA/IIB Disease

• Seminoma with lymph nodes ≤3 cm: radiotherapy or multi-agent cisplatin-based chemotherapy (both achieve >97% cancer-specific survival) 2
• Seminoma with lymph nodes >3 cm: chemotherapy is recommended 2
• Non-seminoma with normal post-orchiectomy markers: RPLND or chemotherapy 2
• Non-seminoma with elevated/rising markers: risk-appropriate multi-agent chemotherapy 2

Critical Pitfalls to Avoid

• Do not delay treatment in symptomatic patients with high tumor burden and elevated markers while attempting biopsy—start chemotherapy immediately when clinical picture is clear 1
• Do not use pediatric protocols for post-pubertal males <18 years; treat according to adult guidelines to avoid inferior outcomes 2
• Do not obtain routine contralateral testis biopsy; the majority of European experts do not consider this indicated 1
• Avoid overtreatment by repeating imaging 6-8 weeks later if initial findings are equivocal (borderline lymph node enlargement) 2

Fertility and Hormonal Considerations

• Offer semen analysis and sperm cryopreservation to all patients, preferably before orchiectomy 1
• Sperm preservation is the most cost-effective fertility preservation strategy 1
• Monitor for hypogonadism and testosterone deficiency during follow-up 2

Contralateral Testis Surveillance

• Approximately 5% of patients develop contralateral germ cell neoplasia in situ (GCNIS), with highest risk in men with testicular atrophy (<12 ml volume) and age <40 years 1
• Physical examination and ultrasound monitoring during follow-up is recommended 1
• If GCNIS is detected, management options include surveillance, radiation (18-20 Gy), or orchiectomy—not chemotherapy 2